OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
45590057

Angel Robotics Co Ltd

Medical Equipment, Supplies & DistributionVerified

Angel Robotics maintains a strong liquidity position with KRW 3.15 billion in cash and equivalents, supported by a current ratio of 23.43, indicating robust short-term asset coverage over liabilities. However, the company's operating cash flow is negative at KRW -7.22 billion, and free cash flow is KRW -8.86 billion, reflecting ongoing operational cash outflows. The debt-to-equity ratio of 0.04 suggests minimal leverage, with long-term debt at KRW 1.22 billion against total equity of KRW 32.63 billion. Profitability metrics are sharply negative, with a return on equity of -29.78% and return on assets of -26.23%, both well below the typical thresholds for medical equipment firms. The company reported a net loss of KRW 9.72 billion and an operating loss of KRW 10.28 billion, despite generating KRW 4.64 billion in revenue. These results indicate significant underperformance relative to industry norms and suggest operational inefficiencies or pricing pressures. The company's revenue is concentrated in its core rehabilitation and industrial wearable products, with no disclosed geographic diversification beyond South Korea. This lack of geographic spread increases exposure to local economic and regulatory shifts. No material segment disclosures are available, but the absence of international revenue suggests a high concentration risk in the domestic market. Looking ahead, the company is projected to maintain negative operating and free cash flows, with no clear path to profitability in the near term. The operating loss is expected to persist, and the company's capital expenditures of KRW -980.47 million indicate ongoing investment in infrastructure or R&D. These factors suggest a challenging growth trajectory, with no significant revenue acceleration or margin improvement in sight. Risk factors include the company's negative cash flows and lack of profitability, which could pressure liquidity if operating performance does not improve. The risk assessment indicates low dilution and liquidity risk, but the absence of profitability raises concerns about long-term sustainability. No immediate dilution threats are identified, and the company has not issued additional shares recently. Recent filings and transcripts do not disclose material events or strategic shifts. The company remains focused on its core wearable robotics and industrial safety products, with no announced expansion into new markets or product lines.

30-day price · 455900+600.00 (+2.2%)
Low$24600.00High$32200.00Close$27850.00As of21 May, 00:00 UTC
Profile
CompanyAngel Robotics Co Ltd
Ticker455900.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Angel Robotics Co Ltd designs and sells gait rehabilitation wearable robots and industrial safety wearable suits in South Korea.

Classification. The company is classified in the Medical Equipment, Supplies & Distribution industry under the Healthcare Services & Equipment business sector with 92% confidence.

Angel Robotics maintains a strong liquidity position with KRW 3.15 billion in cash and equivalents, supported by a current ratio of 23.43, indicating robust short-term asset coverage over liabilities. However, the company's operating cash flow is negative at KRW -7.22 billion, and free cash flow is KRW -8.86 billion, reflecting ongoing operational cash outflows. The debt-to-equity ratio of 0.04 suggests minimal leverage, with long-term debt at KRW 1.22 billion against total equity of KRW 32.63 billion. Profitability metrics are sharply negative, with a return on equity of -29.78% and return on assets of -26.23%, both well below the typical thresholds for medical equipment firms. The company reported a net loss of KRW 9.72 billion and an operating loss of KRW 10.28 billion, despite generating KRW 4.64 billion in revenue. These results indicate significant underperformance relative to industry norms and suggest operational inefficiencies or pricing pressures. The company's revenue is concentrated in its core rehabilitation and industrial wearable products, with no disclosed geographic diversification beyond South Korea. This lack of geographic spread increases exposure to local economic and regulatory shifts. No material segment disclosures are available, but the absence of international revenue suggests a high concentration risk in the domestic market. Looking ahead, the company is projected to maintain negative operating and free cash flows, with no clear path to profitability in the near term. The operating loss is expected to persist, and the company's capital expenditures of KRW -980.47 million indicate ongoing investment in infrastructure or R&D. These factors suggest a challenging growth trajectory, with no significant revenue acceleration or margin improvement in sight. Risk factors include the company's negative cash flows and lack of profitability, which could pressure liquidity if operating performance does not improve. The risk assessment indicates low dilution and liquidity risk, but the absence of profitability raises concerns about long-term sustainability. No immediate dilution threats are identified, and the company has not issued additional shares recently. Recent filings and transcripts do not disclose material events or strategic shifts. The company remains focused on its core wearable robotics and industrial safety products, with no announced expansion into new markets or product lines.
Key takeaways
  • Angel Robotics has strong liquidity but is unprofitable, with negative returns on equity and assets.
  • The company's revenue is concentrated in South Korea, with no disclosed international exposure.
  • Operating and free cash flows are negative, indicating ongoing cash outflows.
  • No immediate dilution or liquidity risks are identified, but profitability remains a concern.
  • The company is investing in capital expenditures, suggesting ongoing R&D or infrastructure development.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$4.64B
Gross profit$2.61B
Operating income-$10.28B
Net income-$9.72B
R&D
SG&A
D&A
SBC
Operating cash flow-$7.22B
CapEx-$980.5M
Free cash flow-$8.86B
Total assets$37.03B
Total liabilities$4.41B
Total equity$32.63B
Cash & equivalents$3.15B
Long-term debt$1.22B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$32.63B
Net cash$1.93B
Current ratio23.4
Debt/Equity0.0
ROA-26.2%
ROE-29.8%
Cash conversion74.0%
CapEx/Revenue-21.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric455900Activity
Op margin-221.4%13.3% medp25 5.9% · p75 13.5%bottom quartile
Net margin-209.3%8.6% medp25 2.7% · p75 12.7%bottom quartile
Gross margin56.3%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-21.1%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity4.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 16:07 UTC#c0522b14
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 16:08 UTCJob: 7e025f74